Compare Public Storage (PSA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Public Storage vs Recursion Pharmaceuticals Inc — how do they compare? Public Storage trades at $311.4 (market cap $54.39B), while Recursion Pharmaceuticals Inc trades at $2.99 (market cap $1.63B). The key difference: Public Storage is far larger — about 33.4× Recursion Pharmaceuticals Inc's market cap, and Public Storage pays a 3.87% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| PSA | RXRX | |
|---|---|---|
Market Cap | $54.39B | $1.63B |
Sector | Real Estate | Health |
52-Week High | $329.64 | $6.79 |
52-Week Low | $258.44 | $2.84 |
Enterprise Value | $68.63B | $1.05B |
Dividend Yield | 3.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Public Storage (PSA) trades at $309.75, down 2.61% on the day, with a bearish technical signal but strong fundamentals including a 39.16% net income margin and consistent earnings beats. Recent developments include the pending acquisition of National Storage Affiliates and a $3.00 dividend payment scheduled for June 30, 2026. The stock is near its 52-week high of $331.00, reflecting investor confidence in its growth trajectory and sector leadership.
The outlook remains positive due to robust profitability, strategic expansions into Canada, and analyst consensus pointing to a $332.25 price target. Key risks include integration challenges from acquisitions and interest rate sensitivity. With 65.72% of analysts rating it Hold, the stock offers steady income potential but requires monitoring of execution risks and market volatility.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
